Denali reports a PhII ALS fail as RIPK1 deal with Sanofi hits another bump
Sanofi and Denali Therapeutics’ partnership ran into yet another stumbling block after their ALS program failed a Phase II study.
DNL788 did not achieve the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
